Expert Interview
Evaluating the Clinical Evidence for CMB-305 in Soft Tissue Sarcoma
Ticker(s): IMDZOncologist with significant experience treating soft tissue sarcoma, particularly synovial sarcoma and myxoid/round cell liposarcoma
How would you characterize the clinical results thus far in a Phase I study of the company's vaccine for heavily pretreated metastatic synovial sarcoma and myxoid/round cell sarcoma? Company claims their cancer vaccine in metastatic STS (synovial sarcoma and myxoid/round cell liposarcoma) (n=24), 80% 1 year survival, with 58% DCR (1 PR/13 SD), PFS 4.6 months.
Company claims as of June 2016 “mOS not reached - median follow up 640 days (21.3 months)”. If the trial is still ongoing, does this mean that mOS is certain to be greater than 640 days (21.3 months)?
What is your experience of the current toxicity of first line olaratumab and doxorubincin?
Added By: festina_lenteAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.